UNCY
Unicycive
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Consensus Rating "Strong Buy"
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About UNCY
Unicycive Therapeutics, Inc.
A biotech company that develops novel treatments for kidney diseases
Biological Technology
08/18/2016
07/13/2021
NASDAQ Stock Exchange
22
12-31
Common stock
4300 El Camino Real, Suite 210, Los Altos, CA 94022
--
Unicycive Therapeutics, Inc., was incorporated in Delaware on August 18, 2016. The company was dormant until July 2017 when it began evaluating some drug candidates for licensing. The company is a biotechnology company that develops treatments for certain medical conditions. Currently, the company's two projects focus on kidney disease. As the company grows and the team is built, the company intends to focus on identifying medical conditions inside and outside kidney disease. The company's current development programs focus on two new therapies: cyanide carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis, and UNI 494 for the treatment of acute kidney injury (AKI).
Company Financials
EPS
UNCY has released its 2025 Q1 earnings. EPS was reported at -0.05, versus the expected -0.06, beating expectations. The chart below visualizes how UNCY has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
